

SECURITIES AND EXCHANGE COMMISSION

FORM NT 10-Q

Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

Filing Date: **2013-05-16** | Period of Report: **2013-03-31**  
SEC Accession No. [0001096906-13-000843](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

**AMEXDRUG CORP**

CIK: **45621** | IRS No.: **952251025** | State of Incorporation: **CA** | Fiscal Year End: **1231**  
Type: **NT 10-Q** | Act: **34** | File No.: **001-10304** | Film No.: **13851921**  
SIC: **5122** Drugs, proprietaries & druggists' sundries

Mailing Address

369 SOUTH DOHENY DR  
SUITE 326  
BEVERLY HILLS CA 90211

Business Address

369 SOUTH DOHENY DR  
SUITE 326  
BEVERLY HILLS CA 90211  
3108550475

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One):  Form 10-K  Form 20-F  Form 11-K  Form 10-Q  Form 10-D  
 Form N-SAR  Form N-CSR

For Period Ended: March 31, 2013  
 Transition Report on Form 10-K  
 Transition Report on Form 20-F  
 Transition Report on Form 11-K  
 Transition Report on Form 10-Q  
 Transition Report on Form N-SAR  
For the Transition Period

Ended: \_\_\_\_\_

*Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.*

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I - REGISTRANT INFORMATION**

AMEXDRUG CORPORATION

Full Name of Registrant

Former Name if Applicable \_\_\_\_\_

7251 Condor Street

Address of Principal Executive Office (*Street and Number*)

Commerce, California 90040

City, State and Zip Code

**PART II - RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

[x] (b)

The subject annual report, semi-annual report; transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
-

**PART III - NARRATIVE**

State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach Extra Sheets If Needed)

The Company’s accounting consultant was not able to complete the financial statements or appropriate adjustments thereto in time for the Company’s auditor to complete the review of the financial statements on a timely basis. As a result the Form 10-Q could not be filed timely.

**PART IV - OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

Robert N. Wilkinson  
(Name)

(801)  
(Area Code)

533-9645  
(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify report(s).  Yes  No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Amexdrug Corporation anticipates reporting net income of approximately \$250,061 for the first fiscal quarter ended March 31, 2013, as compared to \$104,085 of net income reported for the first fiscal quarter ended March 31, 2012.

Amexdrug Corporation.  
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date May 15, 2013

By /s/ Jack Amin  
Jack Amin, President and Chief Executive Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

**ATTENTION**

Intentional Misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).